Relationship between the single nucleotide polymorphism of 5, 1O-methylenetetrahydrofolate reductase gene and the treatment of methotrexate in rheumatoid arthritis
- VernacularTitle:类风湿关节炎亚甲基四氢叶酸还原酶基因多态性与甲氨蝶呤疗效和不良反应的关系
- Author:
Xiaomei ZHOU
;
Jianhua XU
;
Shengqian XU
- Publication Type:Journal Article
- Keywords:
Arthritis,rheumatoid;
5,10-Methylenetetrahydrofolate reductase gene;
Single necleo-tide polymorphism;
Methotrexate;
Efficacy;
Toxicity
- From:
Chinese Journal of Rheumatology
2008;12(9):598-602
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the single nucleotide polymorphism of 5,10-methylenetetrahy-drofolate reduetase gene and its association with the treatment of methotrexate in rheumatoid arthritis (RA).Methods A total of 184 patients with RA were divided into methotrexate (MTX) treatment group, MTX+other DMARDs treatment group, and treatment with other DMARDs but not MTX group. The clinical and laboratory data were evaluated before treatment and 24 weeks later. Efficacy and toxieities of each medication were also analyzed. Real-time fluorescent quantitative PCR was conducted to test gene mutations in RA patients and 100 healthy controls. Results There was no significant difference in the frenqueney of 677CC,CT, "IT and 1298AA, AC, CC between RA patients and the healthy controls. There was significant difference in the frenqueney of 677CC, CT, Tr between RA patients with cardiovascular eomplieations and the healthy controls. In the MTX treatment group, there was significant difference in the frenqueney of 1298AC, CC between the group in which MTX was effective and the other groups in which MTX was not effective, the occurrence rate of side effects of MTX in the patients with 677TT was higher than those without mutation(CC).In MTX+other DMARDs group, the occurrence rate of side effects of MTX in the patients with 677TT and CT was higher than that without mutation (CC). Conclusion There is no relationship between the pathogenesis of RA and the 677C/T, 1298A/C mutation of MTHFR gene. MTHFR gene 677C/T mutation is probably one of the genetic risk factors for cardiovascular complications of RA patients and the side effects of MTX. MTHFR gene 1298A/C allel is associated with the efficacy of MTX.
